September 24, 2020 — The COVID-19 pandemic has forced clinical trial stakeholders to rethink the paradigm as sponsors adapt to site restrictions, remote monitoring, and updated regulatory guidance. This is especially true in precision medicine programs, which have developed global footprints in order to reach targeted patient populations and rely on specialty labs running complex assays to assess safety, characterize patient response and drug MoA, and provide insights into efficacy. In the absence of consistent and predictable in-person presence, how can sponsors maintain the timely visibility necessary to optimize operations of these complex trials?